April 12, 2024 Meeting of the Oncologic Drugs Advisory Committee (ODAC)
Published 2024-04-12
The Committee will discuss the use of minimal residual disease (MRD) as an endpoint in multiple myeloma clinical trials, including considerations regarding timing of assessment, patient populations, and trial design for future studies that intend to use MRD to support accelerated approval of a new product or a new indication.
